An International Delphi Consensus on the Management of Pollen-Food-Allergy Syndrome: A Work Group Report of the AAAAI Adverse Reactions to Foods Committee.

Autor:	Al-Shaikhly T; Section of Allergy, Asthma & Immunology, Department of Medicine, Penn State College of Medicine, Hershey, Pa. Electronic address: talshaikhly@pennstatehealth.psu.edu., Cox A; Department of Pediatrics, Division of Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY., Nowak-Wegrzyn A; Department of Pediatrics, Hassenfeld Children's Hospital, NYU R. Grossman School of Medicine, New York, NY; Department of Pediatrics, Gastroenterology and Nutrition, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland., Cianferoni A; Division of Allergy and Immunology, The Children's Hospital of Philadelphia, Philadelphia, Pa., Katelaris C; Immunology and Allergy Unit, Department of Medicine, Campbelltown Hospital and Western Sydney University, Sydney, New South Wales, Australia., Ebo DG; University of Antwerp, Faculty of Medicine and Health Sciences, Department of Immunology, Allergology, Rheumatology and the Infla-Med Centre of Excellence, Antwerp (Belgium) and Immunology, Allergology, Rheumatology, Antwerp University Hospital, Antwerp, Belgium; Department of Immunology and Allergology, AZ Jan Palfijn Gent, Ghent, Belgium., Konstantinou GN; Department of Allergy and Clinical Immunology, 424 General Military Training Hospital, Thessaloniki, Greece., Brucker H; Southdale Allergy and Asthma Clinic, Minneapolis, Minn., Yang HJ; Department of Pediatrics, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea., Protudjer JLP; Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Man, Canada; Children's Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada., Boechat JL; Basic and Clinical Immunology Unit and CINTESIS@RISE, Faculty of Medicine, University of Porto, Porto, Portugal., Yu JE; Division of Allergy, Immunology, and Rheumatology, Department of Pediatrics, Columbia University Irving Medical Center, New York, NY., Wang J; Department of Pediatrics, Division of Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY., Hsu Blatman KS; Section of Allergy and Clinical Immunology, Department of Medicine, Dartmouth Hitchcock Medical Center, Geisel School of Medicine, Lebanon, NH., Blazowski L; Department of Allergology and Pulmonology, National Research Institute of Tuberculosis and Lung Diseases, Rabka-Zdroj, Poland; Department of Pathophysiology, Institute of Medical Sciences of Rzeszow University, Rzeszow, Poland., Anand MP; Department of Respiratory Medicine, JSS Medical College, JSSAHER, Mysore, Karnataka, India., Ramesh M; Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY., Torres MJ; Allergy Clinical Unit, Department of Medicine and Dermatology, Hospital Regional Universitario de Málaga-UMA-IBIMA, Málaga, Spain., Holbreich M; Allergy and Asthma Consultants, Indianapolis, Ind., Goodman R; Department of Food Science and Technology, University of Nebraska-Lincoln, Lincoln, Neb., Wasserman RL; Department of Pediatrics, Medical City Children's Hospital, Dallas, Texas., Hopp R; Department of Pediatrics, University of Nebraska Medical Center, Omaha, Neb., Sato S; Clinical Research Center for Allergy and Rheumatology, NHO Sagamihara National Hospital, Kanagawa, Japan., Skypala I; Royal Brompton & Harefield Hospitals, part of Guys & St. Thomas National Health Services (NHS) Foundation Trust, London, UK.
Jazyk:	angličtina
Zdroj:	The journal of allergy and clinical immunology. In practice [J Allergy Clin Immunol Pract] 2024 Nov 02. Date of Electronic Publication: 2024 Nov 02.
DOI:	10.1016/j.jaip.2024.09.037
Abstrakt:	Background: Pollen-food-allergy syndrome (PFAS) is common among patients with allergic rhinitis. Treatment recommendations for patients with PFAS remain variable. Objective: To develop consensus recommendation statements for managing patients with PFAS. Methods: An international panel of allergists, researchers, and nutritionists with an interest in PFAS from 25 different institutions across 11 countries convened and a list of statements was written by 3 authors. The RAND/University of California Los Angeles methodology was adopted to establish consensus on the statements. Results: After 2 Delphi rounds, a consensus was reached on 14 statements. The panel agreed that patients with PFAS would benefit from counseling on the nature and basis of PFAS and the rare chance of more severe systemic reactions and their recognition. The panel agreed on avoiding the raw food responsible for the index reaction, but not potentially cross-reactive fruits/vegetables based on the responsible food of the index reaction. Epinephrine autoinjectors should be recommended for patients with PFAS who experienced severe symptoms (beyond the oropharynx) or for patients considered at risk for severe reactions. The panel agreed that the benefit of allergen immunotherapy remains unclear and that PFAS should not be considered the primary indication for such intervention. Conclusions: We developed consensus statements regarding counselling patients about the nature and severity of PFAS, potential risk factors, dietary avoidance, epinephrine autoinjector prescription, and allergen immunotherapy consideration for patients with PFAS. (Copyright © 2024 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu